FibriCheck was founded in 2014 and has pioneered since that date. Today, the FibriCheck family counts approximately 35 employees and some key realisations/numbers to date:
- global market access with medical device approvals in Europe, USA, Australia, Middle-East and Singapore
- successful implementations across the patient lifecycle including targeted prevention (for at risk members), palpitation/symptom management (often for worried people including those suffering with mental health conditions), detection of atrial fibrillation and monitoring post-diagnosis
- >600,000 end-users
- reimbursed via public and private insurers replacing up to 30% of ECG/Holters in routine care
- unique database of ±15 million annotated datasets
- 5 international patents pending with 4 of them close to being granted
Born out of a hospital mobile health unit, FibriCheck started when the father of our co-Founder and CEO suffered a stroke due to atrial fibrillation (AF), the most common cardiac arrhythmia. Despite affecting millions, its intermittent nature makes early detection challenging and management of AF complex and time-consuming.
Driven to radically innovate, co-founders Lars Grieten, Bieke Van Gorp, Jo Van der Auwera and Kobe Leysen pooled their expertise in clinical, business, regulatory, data science and technology to bring timely and scalable detection to more people. By simply transforming individuals’ owned smartphones and watches into medical devices, FibriCheck is increasing access to effective and cost-saving care.